Effect of Non-Surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Biomarker Levels

NCT ID: NCT06175624

Last Updated: 2025-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-01

Study Completion Date

2024-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Periodontal diseases are one of the most common inflammatory diseases. Periodontitis results from products and antigens of microorganisms, which stimulates the innate immune system and local inflammatory response; characterized by gingival inflammation, attachment loss, and alveolar bone destruction. Molecules that play a role in the pathogenesis of periodontal disease can be used as biomarkers in the early diagnosis of periodontitis, in determining the rate of periodontal destruction, and in evaluating the response to periodontal treatment.

CTRPs (C1q/TNF-related proteins), which are adiponectin paralogs, are involved in inflammation, lipid, and glucose metabolism, as well as physiological and pathological processes like vasodilation. CTRP-1 is a glycoprotein belonging to the CTRP family that can be detected in serum in the presence of certain antibodies. Serum CTRP-1 levels increase in type 2 diabetes, prediabetes, coronary artery diseases, congestive heart failure, and atherosclerosis. Lipopolysaccharides found in Gram-negative bacteria cell walls stimulate the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1 β, as well as indirectly increasing the production of CTRP-1. CTRP-1 is a therapeutic target in many inflammatory diseases, including periodontal diseases. However, there are no clinical studies on the role of CTRP-1 in the pathogenesis of periodontal disease. Based on these findings, the goal of our research is to examine the effects of periodontal disease on CTRP-1, IL-10, and TNF-α levels in serum and gingival crevicular fluid samples taken before and after periodontal treatment from periodontally healthy individuals and individuals with gingivitis and periodontitis, and also determine whether CTRP-1 is a potential biomarker that can be used in the diagnosis of periodontal disease.

25 patients with periodontitis, 25 with gingivitis and 25 healthy periodontals (total of 75 individuals) will be included in our study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, and bleeding on probing), serum and gingival crevicular fluid samples will be taken from all individuals. Non-surgical periodontal treatment will be applied in quadrant wise within 2 weeks to individuals with gingivitis and periodontitis. 12 weeks after treatment; the clinical measurements and the collection of serum and gingival crevicular fluid will be repeated. Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis Gingivitis Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

25 patients with periodontitis, 25 with gingivitis and 25 healthy periodontals (total of 75 individuals) will be included in our study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, and bleeding on probing), serum and gingival crevicular fluid samples will be taken from all individuals. Non-surgical periodontal treatment will be applied in quadrant wise within 2 weeks to individuals with gingivitis and periodontitis. 12 weeks after treatment; the clinical measurements and the collection of serum and gingival crevicular fluid will be repeated. Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clinical Healthy

Our study will include 25 people with clinically healthy patients.

Group Type ACTIVE_COMPARATOR

Clinically Helathy

Intervention Type OTHER

Our study will include 25 people with clinically healthy patients.

Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.

CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study.

Gingivitis

Our study will include 25 people with gingivitis patients.

Group Type EXPERIMENTAL

Gingivitis

Intervention Type OTHER

Our study will include 25 people with gingivitis patients.

Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.

CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study.

Periodontitis

Our study will include 25 people with periodontitis patients.

Group Type EXPERIMENTAL

Periodontitis

Intervention Type OTHER

Our study will include 25 people with periodontitis patients.

Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.

CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinically Helathy

Our study will include 25 people with clinically healthy patients.

Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.

CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study.

Intervention Type OTHER

Gingivitis

Our study will include 25 people with gingivitis patients.

Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.

CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study.

Intervention Type OTHER

Periodontitis

Our study will include 25 people with periodontitis patients.

Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.

CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Periodontal healthy group
* Stage III Grade B Periodontitis Group
* To meet the above-mentioned periodontal health and disease criteria

Exclusion Criteria

* Periodontal tissues, periodontal disease course, periodontal application training and to have,
* Chronic alcohol and cigarette use,
* Oral contraceptive use, pregnancy, pregnant,
* Use of antibiotics or anti-inflammatory drugs within the last 6 months,
* Having undergone periodontal treatment in the last 6 months.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biruni University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Burcu KARADUMAN

Proffesor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Biruni Üniversity

Istanbul, Zeytinburnu, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-KAEK-79-23-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.